Gustavo Velasquez, MD, MPH
|Northwestern University Feinberg School of Medicine||MD||2009|
|Harvard T.H. Chan School of Public Health||MPH||2009||Quantitative Methods and Infectious Disease Epidemiology|
|Brigham and Women's Hospital||Residency||2013||Internal Medicine and Global Health Equity|
|Massachusetts General Hospital and Brigham and Women's Hospital||Fellowship||2015||Infectious Diseases|
|University of California, San Francisco||2022||Diversity, Equity, and Inclusion Champion Training|
Dr. Velásquez is an Assistant Professor of Medicine in the Division of HIV, Infectious Diseases, and Global Medicine at the University of California, San Francisco. He is an infectious disease physician and clinical researcher focused on the development of treatment regimens for drug-susceptible and drug-resistant tuberculosis (TB), with a special interest in the safety and tolerability of TB treatment. He works with the endTB consortium (www.endTB.org) and serves as a co-investigator in two multi-country Phase 3 randomized controlled clinical trials evaluating novel shortened oral regimens for multidrug-resistant TB (MDR-TB), specifically fluoroquinolone-susceptible MDR-TB (endTB, NCT02754765) and fluoroquinolone-resistant MDR-TB (endTB-Q, NCT03896685), and in the trials’ pharmacokinetic and pharmacodynamic (PK/PD) sub-study (PandrTB, NCT03827811). He is supported by an NIH/NIAID Mentored Clinical Scientist Research Career Development Award (K08 AI141740) which leverages his role in the trials above to examine the safety, tolerability, and PK/PD of new and repurposed drugs for MDR-TB. Dr. Velásquez serves as an Investigator in the AIDS Clinical Trials Group’s TB Transformative Science Group. He attends on the inpatient ID service and outpatient HIV and TB clinics at San Francisco General Hospital.